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S252 Poster Session I(HIE), cerebral palsy (CP) or congenital hydrocephalus. Most of the
CB units (CBU) were privately banked through parental initiatives at
the time of the baby’s birth. Variable testing was performed by the
banks at the time of CB cryopreservation and storage. From 2004
to 2010, the program was approached by thousands of families seek-
ing treatment for their children. Their calls, emails and letters were
catalogued in a database and characterized.
CBUs were shipped to Duke from private cord blood banks (CBB)
for administration after prequalification of CBB records. To qualify,
the number of total nucleated cells had to deliver 1X10e7 cells/kg of
recipient body weight, have negative donor screening tests and neg-
ative sterility cultures. Patient andCB samples were testedwithHLA
low-resolution typing to confirm patient/unit match. ACB reference
sample was also shipped to Duke for potency testing including enu-
meration of colony forming units, viability and CD34 counts. Upon
confirmation of eligibility, shipment was arranged by Duke’s Stem
Cell Laboratory and the private CBB.
From March 2004 to December 2010, the PBMT program re-
ceived approximately 2,667 inquiries about CB stem cell treatment
for children with brain injuries. Of those, 745 parents had privately
banked their child’s CB. When asked to provide the CB report
from the CBB, 139 did not send a report and had no further contact
with the program. Some children (351) were ineligible: 264 due to
patient reasons including diagnosis (165), incomplete records (81),
and parents declining (10); and 91 due to CB reasons including
low cell count (57), positive sterility cultures (24), and bank issues
(10). A total of 255 children were successfully infused with their
own CB without any serious adverse events. Units were shipped
from 57 different CBBs.
In summary, 27.9% of contacts had privately stored their baby’s
CB.Of these, 34.2%were eligible for infusion.Of ineligible patients,
25.9% were due to problems with CBU quality. The infusions were
well tolerated (Sun et al, Transfusion 2010). Studies to determine ef-
ficacy in babies and children with HIE, CP and congenital hydro-
cephalus are ongoing.129
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Introduction: In recent years a theory of a possible reconstitution of
the immune system using autologous hematopoietic stem cell trans-
plantation (A-HSCT) has emerged, in this basis and because of the
pathogenesis, patients with newly diagnosis of type 1 diabetes melli-
tus (DM-1) may benefit with this therapy.
Objective: To quantify the decrease in insulin requirements in pa-
tients with DM-1 who underwent A-HSCT using reduced-intensity
conditioning (RIC).
Material and Methods: Prospective and experimental study, in
which have been included 8 patients with newly diagnosed DM-1,
confirmed by measurement of seric anti-GAD antibodies and pan-
creatic reserve measured from C-peptide levels, in whom was per-
formed A-HCT using RIC on an outpatient basis. A two-day
ciclofosfamide (CFM) scheme as well as G-CSF was used for mobi-
lization. The conditioning regimen was based on a four-day CFM
and fludarabine.
Results:Of the 8 cases, 6 patients had received the therapy, and 2 are
in process; 5 male and 3 female patients, median of age was found in
12.5 (4-18), and the median time from the diagnosis of DM-1 is 3
months (0-9). During the 2-16 months follow-up (median 12) of pa-
tients who underwent the procedure, 2 are currently free from insu-
lin use and the remaining have decreased their use by 80%, 50%,
35% and 0% respectively; the mean amount of CD34 + cells infused
is in 10.41x106 (3.78-19.3 x 106). In 5 of the 6 patients only one rec-
ollection procedure were needed, the other patient required a sec-
ond.
Conclusion: After 12 months follow-up, 5/6 patients had showed
a decrease in the insulin requirements and none patient had devel-
oped any complication or needed hospitalization.
Trial Registration.ClinicalTrials.gov Identifier: NCT01121029.130
2MELPHALAN 180mg/m CAN BE SAFELY ADMINISTERED AS CONDITION-
ING REGIMEN PRIOR TO AN AUTOLOGOUS STEM CELL TRANSPLANTA-
TION IN MULTIPLE MYELOMA PATIENTS WITH CREATININE
CLEARANCE#60ml/min/1.73 m2 WITH USE OF PALIFERMIN FOR CYTO-
PROTECTION: RESULTS OF A PHASE I TRIAL
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The majority of multiple myeloma (MM) patients (pts) with ab-
normal renal function (AbRF) receive attenuated dose of therapy.
Melphalan (M) is the most effective conditioning for MM pts receiv-
ing autologous stem cells transplant (ASCT). M 140 mg/m2 is the
standard of care in pts with AbRF, asM 200mg/m2 resulted in severe
oral mucositis (OM). Palifermin (P) as a cytoprotective agent has
demonstrated efficacy in reducing the intensity & duration of OM.
Due to lack of prospective data on the use of P in MM pts with
AbRF, we designed this study to determine the maximum tolerated
dose (MTD) of M when used with P, in order to decrease OM.
Methods: Eligibility criteria: creatinine clearance# 60ml/min/1.73
m2, age $18 years, Durie-Salmon stage 2/3, ECOG PS # 2, no di-
alysis, no active OM & a suitable candidate for ASCT. Level (L) 1
began at M 140 mg/m2 with P 60 mcg/kg/d, given as I.V bolus on
Day -5,-4, -3 and Day +1, +2 & +3 (Stem cells infused on Day 0).
Mwas given onD-2& dose-escalation proceeded at 20mg/m2 incre-
ments, up to a maximum dose of 200 mg/m2 in L4. If no symptom-
atic G$ 3 dose limiting toxicities (DLTs) were noted, an additional
cohort of 3 pts was entered at the next dose level. Dose escalations
were to stop if $ 2 DLTs occurred at a M dose (MTD). Grade
(G) 4 OM, G4 diarrhea, $ G3 rash, & $ G3 cardiac toxicity were
considered as DLT; G 3/4 hematological toxicity was acceptable.
The G of OM was assessed daily (WHO OM scale-G 0-4).
Results:Nineteen pts were enrolled from 06/2007 to 06/2011. Data
on 15 evaluable pts is reported as 4 pts were removed. Median age
was 59 years (36-67).
Table.
Patient Characteristics (N 5 15)Sex – Male- no. (%) 8 (53)
Median Age- yr (Range) 59 (36-67)
Race- Caucasian- no. (%) 12 (80)
Median Creatinine clearance (Range) 42.8 (29-60)






Median no. of infused CD34+ cells x
10^6/Kg (Range)
4.2 (2.6 - 8.0)Median number of days to neutrophil
engraftment (Range)12 (11-21)Median number of days to platelet
engraftment (Range)19 (0 - 86)Median duration of hospitalization-
days (Range)16 (12 -74)The overall incidence of OM$G3 was 53% (8/15) and a median
duration of$G3OMwas 6.5 days (3-42). One patient in L2 (M 160
mg/m2) developed atrial fibrillation. Two pts in L4 (M 200mg/m2)
developed G4 OM, hence reaching DLT. Three more pts were
then enrolled in L3 (M 180mg/m2). No DLT was observed in 6
pts enrolled in L3. Fourteen pts were evaluable for response at
D+100 (4 CRs). One patient died in L4 due to multi-organ failure
and infection. The most common adverse events include rash (13
events, no G 3), asymptomatic elevation of amylase (9, 3 pts G 3)
and lipase (2, 1 pt G 3) and diarrhea (12, 1 pt G 3 (C.Difficile +ve)).
Nine pts required narcotics; 4 pts neededTPN/NG feeding.Median
duration of hospitalization for ASCT was 16 days (12-74).
